Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
AUM Biosciences works in Biotechnology Research, out of Singapore. Ownership is privately held; it publishes at aumbiosciences.com. The record carries three addresses across three office countries. The record counts 19 people. Tagged biotech, oncology and cancer. One Singapore registration (UEN) is a confirmed match. The latest round on record is Series A at US$27.0M. The record links four similar brands, most of them in Biotechnology Research.
UEN201810204D
| AUM BIOSCIENCES PTE. LTD. | UEN 201810204D |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
| Countries | 3 |
|---|---|
| Primary country | SG |
All codes: SG AU US
| Rounds | 2 |
|---|---|
| Axis | 2018 to 2026 |
| Series A · 12 Nov 2021 | US$ 27.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
One Singapore entity on ACRA. AUM BIOSCIENCES PTE. LTD. (UEN 201810204D), high confidence.
The record holds 19 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Three addresses on record across 3 countries. Primary: 10 Collyer Quay, Level 40, Singapore 049315.
Two rounds. Latest 12 November 2021: Series A, US$27,000,000, investors SPRIM and Everlife.
Eight tags on the brand's own list, among them biotech, oncology and cancer.
Four peer profiles on record: Biotech Connection Singapore and ACM Biolabs.